 Clyde Wright
Concepts (351)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 21 | 2024 | 379 | 7.540 |
Why?
| | NF-kappa B | 23 | 2024 | 665 | 7.300 |
Why?
| | Respiratory Distress Syndrome, Newborn | 12 | 2023 | 103 | 7.050 |
Why?
| | Acetaminophen | 14 | 2024 | 247 | 6.600 |
Why?
| | Endotoxemia | 10 | 2024 | 86 | 6.320 |
Why?
| | Pulmonary Surfactants | 10 | 2023 | 106 | 5.760 |
Why?
| | I-kappa B Proteins | 13 | 2022 | 79 | 4.740 |
Why?
| | Liver | 16 | 2024 | 1842 | 4.350 |
Why?
| | Continuous Positive Airway Pressure | 12 | 2022 | 78 | 3.810 |
Why?
| | Ductus Arteriosus, Patent | 8 | 2024 | 49 | 3.770 |
Why?
| | Lung Injury | 7 | 2022 | 211 | 3.220 |
Why?
| | Immunity, Innate | 10 | 2024 | 805 | 2.830 |
Why?
| | Infant, Premature, Diseases | 5 | 2021 | 93 | 2.820 |
Why?
| | Infant, Newborn | 46 | 2024 | 5756 | 2.790 |
Why?
| | Lung | 19 | 2024 | 3938 | 2.640 |
Why?
| | Noninvasive Ventilation | 5 | 2022 | 49 | 2.590 |
Why?
| | Infant, Premature | 15 | 2024 | 542 | 2.580 |
Why?
| | Signal Transduction | 18 | 2024 | 4931 | 2.220 |
Why?
| | Hyperoxia | 7 | 2017 | 90 | 1.960 |
Why?
| | Transcription Factor RelA | 4 | 2024 | 84 | 1.870 |
Why?
| | Animals, Newborn | 13 | 2024 | 835 | 1.830 |
Why?
| | Surface-Active Agents | 8 | 2023 | 84 | 1.780 |
Why?
| | Infant, Extremely Premature | 8 | 2024 | 61 | 1.760 |
Why?
| | Mice, Inbred ICR | 12 | 2021 | 111 | 1.740 |
Why?
| | Ibuprofen | 5 | 2024 | 81 | 1.520 |
Why?
| | Lipopolysaccharides | 9 | 2024 | 877 | 1.480 |
Why?
| | Biological Products | 3 | 2021 | 205 | 1.450 |
Why?
| | Toll-Like Receptor 4 | 3 | 2023 | 264 | 1.430 |
Why?
| | Chemical and Drug Induced Liver Injury | 2 | 2022 | 132 | 1.420 |
Why?
| | Oxygen | 6 | 2022 | 915 | 1.400 |
Why?
| | Macrophages | 7 | 2020 | 1488 | 1.300 |
Why?
| | Apoptosis | 6 | 2024 | 2492 | 1.290 |
Why?
| | Neonatology | 2 | 2021 | 22 | 1.240 |
Why?
| | Airway Extubation | 2 | 2020 | 54 | 1.170 |
Why?
| | Evidence-Based Medicine | 4 | 2021 | 712 | 1.160 |
Why?
| | NF-kappa B p50 Subunit | 4 | 2023 | 24 | 1.160 |
Why?
| | Inflammation | 4 | 2024 | 2750 | 1.120 |
Why?
| | Mice | 28 | 2024 | 16961 | 1.110 |
Why?
| | Animals | 38 | 2024 | 35391 | 1.090 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2024 | 1202 | 1.080 |
Why?
| | Infant, Newborn, Diseases | 2 | 2019 | 110 | 1.010 |
Why?
| | Humans | 70 | 2024 | 129625 | 0.930 |
Why?
| | Pregnancy | 14 | 2024 | 6417 | 0.930 |
Why?
| | Transcription Factor AP-1 | 1 | 2024 | 88 | 0.860 |
Why?
| | Disease Models, Animal | 12 | 2024 | 4078 | 0.830 |
Why?
| | Fetal Growth Retardation | 4 | 2024 | 550 | 0.830 |
Why?
| | Physician's Role | 2 | 2021 | 206 | 0.820 |
Why?
| | Gene Expression Regulation | 8 | 2021 | 2542 | 0.810 |
Why?
| | Interleukin-1alpha | 2 | 2020 | 56 | 0.790 |
Why?
| | Mice, Inbred C57BL | 11 | 2024 | 5455 | 0.770 |
Why?
| | Premature Birth | 3 | 2022 | 317 | 0.760 |
Why?
| | Interleukin-1beta | 3 | 2020 | 372 | 0.750 |
Why?
| | Cytochrome P-450 CYP2E1 | 4 | 2023 | 25 | 0.740 |
Why?
| | Streptozocin | 1 | 2021 | 20 | 0.730 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2021 | 285 | 0.730 |
Why?
| | Selenoproteins | 1 | 2020 | 7 | 0.710 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2024 | 80 | 0.670 |
Why?
| | Toll-Like Receptor 9 | 1 | 2020 | 31 | 0.670 |
Why?
| | Oxidative Stress | 3 | 2017 | 1266 | 0.660 |
Why?
| | Ovarian Follicle | 1 | 2020 | 64 | 0.660 |
Why?
| | Monocytes | 1 | 2023 | 553 | 0.660 |
Why?
| | Chorioamnionitis | 1 | 2020 | 40 | 0.660 |
Why?
| | Acidosis | 1 | 2020 | 89 | 0.630 |
Why?
| | Oximetry | 2 | 2017 | 87 | 0.620 |
Why?
| | Uterus | 1 | 2020 | 207 | 0.620 |
Why?
| | Emphysema | 1 | 2019 | 109 | 0.610 |
Why?
| | Interferon-beta | 1 | 2018 | 89 | 0.590 |
Why?
| | Gestational Age | 4 | 2024 | 876 | 0.590 |
Why?
| | Inflammation Mediators | 3 | 2019 | 505 | 0.580 |
Why?
| | I-kappa B Kinase | 2 | 2021 | 54 | 0.580 |
Why?
| | Fetus | 4 | 2020 | 774 | 0.580 |
Why?
| | Treatment Failure | 2 | 2019 | 339 | 0.570 |
Why?
| | Calcium Signaling | 1 | 2020 | 250 | 0.570 |
Why?
| | Respiration, Artificial | 5 | 2022 | 613 | 0.570 |
Why?
| | Sugars | 1 | 2018 | 36 | 0.570 |
Why?
| | Beverages | 1 | 2018 | 68 | 0.560 |
Why?
| | Mediastinal Emphysema | 1 | 2017 | 6 | 0.550 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 253 | 0.540 |
Why?
| | Respiration | 2 | 2018 | 192 | 0.540 |
Why?
| | Gene Expression | 3 | 2024 | 1465 | 0.530 |
Why?
| | Infant, Small for Gestational Age | 1 | 2017 | 85 | 0.530 |
Why?
| | Peer Review, Research | 1 | 2017 | 41 | 0.530 |
Why?
| | Standard of Care | 1 | 2017 | 71 | 0.520 |
Why?
| | Insulin-Secreting Cells | 1 | 2021 | 364 | 0.520 |
Why?
| | Respiratory System | 1 | 2017 | 155 | 0.510 |
Why?
| | Male | 26 | 2024 | 63670 | 0.510 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 235 | 0.510 |
Why?
| | Immune Tolerance | 1 | 2018 | 356 | 0.510 |
Why?
| | Intensive Care Units, Neonatal | 4 | 2022 | 226 | 0.500 |
Why?
| | Asphyxia Neonatorum | 1 | 2016 | 18 | 0.500 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 276 | 0.490 |
Why?
| | Cyclooxygenase 2 | 1 | 2016 | 176 | 0.480 |
Why?
| | Milk, Human | 1 | 2017 | 151 | 0.480 |
Why?
| | Hypothermia, Induced | 1 | 2016 | 76 | 0.470 |
Why?
| | Fetal Diseases | 1 | 2016 | 158 | 0.460 |
Why?
| | Child Advocacy | 2 | 2005 | 32 | 0.460 |
Why?
| | Nitric Oxide | 3 | 2019 | 895 | 0.460 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 584 | 0.450 |
Why?
| | Infant | 10 | 2024 | 8995 | 0.450 |
Why?
| | NF-KappaB Inhibitor alpha | 4 | 2020 | 53 | 0.440 |
Why?
| | Sex Characteristics | 1 | 2019 | 736 | 0.440 |
Why?
| | Intestinal Atresia | 1 | 2014 | 14 | 0.440 |
Why?
| | Endothelin-1 | 1 | 2015 | 179 | 0.430 |
Why?
| | Calcium | 1 | 2020 | 1212 | 0.430 |
Why?
| | Resuscitation | 1 | 2016 | 237 | 0.420 |
Why?
| | Ethics Committees, Research | 1 | 2013 | 41 | 0.420 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2013 | 67 | 0.410 |
Why?
| | Visual Perception | 1 | 2015 | 163 | 0.410 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 189 | 0.410 |
Why?
| | Caloric Restriction | 2 | 2024 | 111 | 0.410 |
Why?
| | Intestine, Small | 1 | 2014 | 151 | 0.400 |
Why?
| | Fibroblasts | 3 | 2015 | 953 | 0.400 |
Why?
| | Pediatrics | 3 | 2005 | 1056 | 0.400 |
Why?
| | Female | 25 | 2024 | 68734 | 0.390 |
Why?
| | Hepatocytes | 3 | 2024 | 216 | 0.390 |
Why?
| | Catheterization, Peripheral | 1 | 2013 | 104 | 0.390 |
Why?
| | Abnormalities, Multiple | 1 | 2014 | 179 | 0.390 |
Why?
| | Phospholipids | 1 | 2013 | 216 | 0.380 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2018 | 1365 | 0.380 |
Why?
| | Clinical Competence | 1 | 2019 | 1017 | 0.370 |
Why?
| | Colon | 1 | 2014 | 254 | 0.370 |
Why?
| | Respiration Disorders | 1 | 2012 | 72 | 0.370 |
Why?
| | Urinary Bladder | 1 | 2014 | 175 | 0.370 |
Why?
| | Fetal Blood | 2 | 2024 | 317 | 0.370 |
Why?
| | Biomarkers | 3 | 2024 | 3968 | 0.360 |
Why?
| | Microcirculation | 1 | 2010 | 145 | 0.340 |
Why?
| | Mice, Knockout | 3 | 2022 | 2881 | 0.340 |
Why?
| | Neuropsychological Tests | 1 | 2015 | 1017 | 0.340 |
Why?
| | Patient Safety | 1 | 2013 | 287 | 0.340 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2021 | 171 | 0.320 |
Why?
| | Glycolysis | 2 | 2021 | 315 | 0.320 |
Why?
| | RAW 264.7 Cells | 2 | 2020 | 49 | 0.320 |
Why?
| | Cells, Cultured | 5 | 2019 | 4084 | 0.320 |
Why?
| | Body Mass Index | 1 | 2017 | 2274 | 0.310 |
Why?
| | Analgesics, Non-Narcotic | 3 | 2024 | 120 | 0.310 |
Why?
| | Cell Line | 4 | 2017 | 2784 | 0.310 |
Why?
| | Indomethacin | 3 | 2024 | 78 | 0.300 |
Why?
| | Curriculum | 2 | 2005 | 920 | 0.300 |
Why?
| | Hydrocortisone | 2 | 2020 | 306 | 0.290 |
Why?
| | MicroRNAs | 2 | 2024 | 679 | 0.280 |
Why?
| | Cognition | 1 | 2015 | 1129 | 0.270 |
Why?
| | Cytokines | 3 | 2023 | 2021 | 0.270 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 903 | 0.260 |
Why?
| | Interleukin-6 | 2 | 2022 | 723 | 0.260 |
Why?
| | Gene Silencing | 2 | 2021 | 190 | 0.250 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2020 | 135 | 0.250 |
Why?
| | Biological Evolution | 1 | 2009 | 436 | 0.240 |
Why?
| | Endothelial Cells | 1 | 2010 | 749 | 0.240 |
Why?
| | History, 20th Century | 2 | 2017 | 294 | 0.240 |
Why?
| | Internship and Residency | 2 | 2005 | 1050 | 0.240 |
Why?
| | Cell Survival | 3 | 2021 | 1076 | 0.230 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2020 | 824 | 0.230 |
Why?
| | RNA, Messenger | 4 | 2024 | 2708 | 0.220 |
Why?
| | Patient Advocacy | 1 | 2005 | 73 | 0.220 |
Why?
| | Cell Nucleus | 2 | 2019 | 584 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2024 | 53 | 0.220 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2024 | 69 | 0.220 |
Why?
| | Toll-Like Receptor 1 | 1 | 2023 | 12 | 0.210 |
Why?
| | Zymosan | 1 | 2023 | 65 | 0.210 |
Why?
| | Intensive Care, Neonatal | 1 | 2023 | 40 | 0.200 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2023 | 86 | 0.200 |
Why?
| | Infant, Low Birth Weight | 1 | 2023 | 135 | 0.200 |
Why?
| | Toll-Like Receptors | 1 | 2023 | 179 | 0.190 |
Why?
| | Age Factors | 2 | 2020 | 3152 | 0.190 |
Why?
| | Ligation | 1 | 2022 | 87 | 0.190 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2024 | 204 | 0.190 |
Why?
| | Morbidity | 2 | 2021 | 302 | 0.190 |
Why?
| | Hepatic Veins | 1 | 2021 | 31 | 0.190 |
Why?
| | Dyspnea | 1 | 2023 | 239 | 0.190 |
Why?
| | Dilatation | 1 | 2022 | 61 | 0.180 |
Why?
| | Feces | 1 | 2024 | 442 | 0.180 |
Why?
| | Insulinoma | 1 | 2021 | 30 | 0.180 |
Why?
| | Transcription Factors | 1 | 2009 | 1647 | 0.180 |
Why?
| | Chemokine CXCL10 | 1 | 2021 | 35 | 0.180 |
Why?
| | Vascular Malformations | 1 | 2021 | 51 | 0.180 |
Why?
| | TNF Receptor-Associated Factor 1 | 1 | 2020 | 8 | 0.180 |
Why?
| | Glutathione Peroxidase | 1 | 2020 | 43 | 0.180 |
Why?
| | C-Reactive Protein | 1 | 2023 | 400 | 0.170 |
Why?
| | Chemokine CCL3 | 1 | 2020 | 17 | 0.170 |
Why?
| | Selenium | 1 | 2020 | 36 | 0.170 |
Why?
| | Portal Vein | 1 | 2021 | 108 | 0.170 |
Why?
| | Ventilator Weaning | 1 | 2020 | 36 | 0.170 |
Why?
| | Homeostasis | 1 | 2024 | 605 | 0.170 |
Why?
| | Oxidative Phosphorylation | 1 | 2021 | 188 | 0.170 |
Why?
| | Chelating Agents | 1 | 2020 | 68 | 0.160 |
Why?
| | Calcineurin Inhibitors | 1 | 2020 | 68 | 0.160 |
Why?
| | Intermittent Positive-Pressure Ventilation | 1 | 2019 | 11 | 0.160 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2020 | 140 | 0.160 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2021 | 183 | 0.160 |
Why?
| | Primary Cell Culture | 1 | 2020 | 164 | 0.160 |
Why?
| | Norepinephrine | 1 | 2020 | 210 | 0.160 |
Why?
| | Proteolysis | 1 | 2020 | 167 | 0.160 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 338 | 0.160 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2019 | 101 | 0.160 |
Why?
| | Chemokine CXCL1 | 1 | 2019 | 72 | 0.160 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2018 | 17 | 0.150 |
Why?
| | Cytosol | 1 | 2019 | 219 | 0.150 |
Why?
| | Spleen | 1 | 2020 | 509 | 0.150 |
Why?
| | Morphogenesis | 1 | 2019 | 158 | 0.150 |
Why?
| | STAT1 Transcription Factor | 1 | 2018 | 69 | 0.150 |
Why?
| | Weight Gain | 2 | 2023 | 509 | 0.150 |
Why?
| | Delivery Rooms | 1 | 2018 | 7 | 0.150 |
Why?
| | Receptors, CCR2 | 1 | 2018 | 40 | 0.150 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 574 | 0.150 |
Why?
| | Consensus | 1 | 2021 | 618 | 0.140 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2018 | 20 | 0.140 |
Why?
| | Rotation | 1 | 2018 | 112 | 0.140 |
Why?
| | Protective Agents | 1 | 2018 | 39 | 0.140 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 77 | 0.140 |
Why?
| | Sheep | 1 | 2020 | 845 | 0.140 |
Why?
| | Overnutrition | 1 | 2017 | 30 | 0.140 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2018 | 145 | 0.140 |
Why?
| | Hypertension, Pulmonary | 2 | 2019 | 1894 | 0.140 |
Why?
| | Pennsylvania | 1 | 2017 | 108 | 0.140 |
Why?
| | Ductus Arteriosus | 1 | 2017 | 72 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 640 | 0.130 |
Why?
| | Parturition | 1 | 2017 | 71 | 0.130 |
Why?
| | Conservative Treatment | 1 | 2017 | 32 | 0.130 |
Why?
| | Positive-Pressure Respiration | 1 | 2017 | 76 | 0.130 |
Why?
| | Calibration | 1 | 2017 | 140 | 0.130 |
Why?
| | Protective Factors | 1 | 2016 | 91 | 0.130 |
Why?
| | Disease Susceptibility | 1 | 2018 | 334 | 0.130 |
Why?
| | Health Status Disparities | 1 | 2019 | 256 | 0.130 |
Why?
| | Time-to-Treatment | 1 | 2018 | 179 | 0.130 |
Why?
| | Primary Prevention | 1 | 2018 | 190 | 0.130 |
Why?
| | History, 21st Century | 1 | 2017 | 186 | 0.130 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 591 | 0.130 |
Why?
| | Vascular Remodeling | 1 | 2018 | 192 | 0.120 |
Why?
| | Up-Regulation | 1 | 2019 | 840 | 0.120 |
Why?
| | Precision Medicine | 1 | 2019 | 387 | 0.120 |
Why?
| | Macaca mulatta | 1 | 2016 | 151 | 0.120 |
Why?
| | Cholestasis | 1 | 2018 | 232 | 0.120 |
Why?
| | Cell Proliferation | 3 | 2011 | 2373 | 0.120 |
Why?
| | Administration, Oral | 1 | 2017 | 787 | 0.110 |
Why?
| | Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2014 | 3 | 0.110 |
Why?
| | Periodicals as Topic | 1 | 2017 | 204 | 0.110 |
Why?
| | Prune Belly Syndrome | 1 | 2014 | 7 | 0.110 |
Why?
| | Body Composition | 1 | 2018 | 649 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 84 | 0.110 |
Why?
| | Adult | 5 | 2024 | 35599 | 0.110 |
Why?
| | Cell Line, Tumor | 1 | 2021 | 3186 | 0.110 |
Why?
| | Interleukins | 1 | 2015 | 241 | 0.100 |
Why?
| | Pilot Projects | 1 | 2018 | 1592 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1501 | 0.100 |
Why?
| | Syndrome | 1 | 2014 | 340 | 0.100 |
Why?
| | Breast Feeding | 1 | 2017 | 423 | 0.100 |
Why?
| | Kidney | 1 | 2020 | 1386 | 0.100 |
Why?
| | Child | 4 | 2018 | 20884 | 0.100 |
Why?
| | Transcriptome | 1 | 2019 | 876 | 0.100 |
Why?
| | Brain Injuries | 1 | 2017 | 466 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1947 | 0.100 |
Why?
| | Hydrogen Peroxide | 1 | 2014 | 317 | 0.100 |
Why?
| | Rats | 2 | 2013 | 5483 | 0.100 |
Why?
| | Software | 1 | 2017 | 608 | 0.100 |
Why?
| | Culture Media, Serum-Free | 1 | 2012 | 49 | 0.100 |
Why?
| | Risk Assessment | 2 | 2019 | 3262 | 0.100 |
Why?
| | Gene Knock-In Techniques | 1 | 2012 | 53 | 0.090 |
Why?
| | Retinopathy of Prematurity | 1 | 2013 | 141 | 0.090 |
Why?
| | Cell Line, Transformed | 1 | 2012 | 141 | 0.090 |
Why?
| | Radiography | 1 | 2014 | 797 | 0.090 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2011 | 14 | 0.090 |
Why?
| | Mice, Mutant Strains | 1 | 2012 | 298 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2720 | 0.090 |
Why?
| | Cohort Studies | 2 | 2019 | 5426 | 0.090 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 342 | 0.090 |
Why?
| | Circadian Rhythm | 1 | 2014 | 413 | 0.090 |
Why?
| | Mice, Transgenic | 1 | 2015 | 2128 | 0.080 |
Why?
| | Protoporphyrins | 1 | 2009 | 16 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 245 | 0.080 |
Why?
| | Cyclin D1 | 1 | 2009 | 63 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1432 | 0.080 |
Why?
| | Heme Oxygenase-1 | 1 | 2009 | 62 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2442 | 0.080 |
Why?
| | Antioxidants | 1 | 2013 | 558 | 0.080 |
Why?
| | Luciferases | 1 | 2008 | 147 | 0.080 |
Why?
| | Child, Preschool | 2 | 2018 | 10490 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 403 | 0.070 |
Why?
| | Genes, Reporter | 1 | 2008 | 265 | 0.070 |
Why?
| | Blood Glucose | 1 | 2018 | 2100 | 0.070 |
Why?
| | Tyrosine | 1 | 2008 | 223 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2008 | 361 | 0.070 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 143 | 0.070 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 283 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2012 | 1687 | 0.070 |
Why?
| | Aging | 1 | 2017 | 1778 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2395 | 0.070 |
Why?
| | Risk Factors | 2 | 2019 | 9786 | 0.070 |
Why?
| | Transfection | 1 | 2008 | 915 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 827 | 0.060 |
Why?
| | Recombinant Proteins | 1 | 2008 | 1308 | 0.060 |
Why?
| | Base Sequence | 1 | 2008 | 2147 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2011 | 1891 | 0.060 |
Why?
| | Wisconsin | 1 | 2005 | 99 | 0.060 |
Why?
| | Pregnancy Trimester, Third | 1 | 2024 | 109 | 0.060 |
Why?
| | Amniotic Fluid | 1 | 2024 | 87 | 0.060 |
Why?
| | Phosphorylation | 1 | 2008 | 1713 | 0.060 |
Why?
| | Prenatal Diagnosis | 1 | 2024 | 194 | 0.050 |
Why?
| | United States | 2 | 2013 | 13871 | 0.050 |
Why?
| | Program Development | 1 | 2005 | 355 | 0.050 |
Why?
| | Educational Measurement | 1 | 2005 | 260 | 0.050 |
Why?
| | Diet, High-Fat | 1 | 2023 | 239 | 0.050 |
Why?
| | Child Health Services | 1 | 2004 | 184 | 0.050 |
Why?
| | DNA | 1 | 2008 | 1404 | 0.050 |
Why?
| | Data Collection | 1 | 2005 | 650 | 0.050 |
Why?
| | Models, Biological | 1 | 2008 | 1724 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2024 | 1042 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2005 | 442 | 0.040 |
Why?
| | Program Evaluation | 1 | 2005 | 875 | 0.040 |
Why?
| | Fetal Development | 1 | 2023 | 288 | 0.040 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2019 | 20 | 0.040 |
Why?
| | Caspases, Initiator | 1 | 2018 | 17 | 0.040 |
Why?
| | Liver X Receptors | 1 | 2018 | 31 | 0.040 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2018 | 37 | 0.040 |
Why?
| | Glucose | 1 | 2023 | 1002 | 0.040 |
Why?
| | Ketanserin | 1 | 2018 | 12 | 0.040 |
Why?
| | Serotonin Antagonists | 1 | 2018 | 31 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2019 | 667 | 0.040 |
Why?
| | Caspase 1 | 1 | 2018 | 143 | 0.040 |
Why?
| | Placenta | 1 | 2024 | 723 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2018 | 123 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2018 | 218 | 0.030 |
Why?
| | Lipoproteins | 1 | 2018 | 172 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3378 | 0.030 |
Why?
| | Caspases | 1 | 2018 | 245 | 0.030 |
Why?
| | Parenteral Nutrition | 1 | 2018 | 104 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 301 | 0.030 |
Why?
| | Bleomycin | 1 | 2018 | 243 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 217 | 0.030 |
Why?
| | Social Determinants of Health | 1 | 2019 | 226 | 0.030 |
Why?
| | Comet Assay | 1 | 2014 | 17 | 0.030 |
Why?
| | Prospective Studies | 1 | 2024 | 7135 | 0.020 |
Why?
| | DNA Damage | 1 | 2014 | 384 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2011 | 53 | 0.020 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 55 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 117 | 0.020 |
Why?
| | Binding Sites | 1 | 2014 | 1248 | 0.020 |
Why?
| | Injections | 1 | 2011 | 174 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 315 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2009 | 24 | 0.020 |
Why?
| | Early Growth Response Protein 1 | 1 | 2009 | 28 | 0.020 |
Why?
| | Hep G2 Cells | 1 | 2009 | 61 | 0.020 |
Why?
| | K562 Cells | 1 | 2009 | 85 | 0.020 |
Why?
| | Response Elements | 1 | 2009 | 90 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2009 | 170 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 813 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 296 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 756 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2024 | 14522 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1250 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2011 | 1075 | 0.010 |
Why?
| | Time Factors | 1 | 2011 | 6555 | 0.010 |
Why?
|
|
Wright's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|